Decreased orotate phosphoribosyltransferase activity produces 5-fluorouracil resistance in a human gastric cancer cell line

Oncology Reports

Volumn 20, Issue 6, 2008, Pages 1545-1551

  Tsutani, Yasuhiro ^a   Yoshida, Kazuhiro ^a,c   Sanada, Yuichi ^a   Wada, Yoshiyuki ^a   Konishi, Kazuo ^a   Fukushima, Masakazu ^b   Okada, Morihito ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

^c GIFU UNIVERSITY   (Japan)

Author keywords

5 fluorouracil; Crossresistance; Docetaxel; Gastric cancer; Orotate phosphoribosyltransferase; Paclitaxel

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BETA TUBULIN; DIHYDROPYRIMIDINE DEHYDROGENASE; DOCETAXEL; FLUOROURACIL; GLYCOPROTEIN P; OROTATE PHOSPHORIBOSYLTRANSFERASE; OXALIPLATIN; PACLITAXEL; PROTEIN BCL 2; SMALL INTERFERING RNA; TAXANE DERIVATIVE; THYMIDYLATE SYNTHASE; ANTINEOPLASTIC AGENT; TAXOID; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG EXPOSURE; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; KNOCKOUT GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; STOMACH CANCER; BIOSYNTHESIS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH TUMOR; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OROTATE PHOSPHORIBOSYLTRANSFERASE; P-GLYCOPROTEIN; PACLITAXEL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; STOMACH NEOPLASMS; TAXOIDS; TETRAZOLIUM SALTS; THIAZOLES;

EID: 59249100546     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000178     Document Type: Article

References (27)

1. Yoshida K, Tanabe K, Ueno H, Ohta K, Hihara J, Toge T and Nishiyama M: Future prospects of personalized chemotherapy in gastric cancer patients: results of a prospective randomized pilot study. Gastric Cancer 6 (Suppl 1): 82-89, 2003.
2. Tanaka T, Tanimoto K, Otani K, Satoh K, Ohtani K, Yoshida K, Toge T, Yahata H, Tanaka S, Chayama K, Okazaki Y, Hayashizaki Y, Hiyama K and Nishiyama M: Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes. Int J Cancer 111: 617-626, 2004.
3. Fumoto S, Shimokuni T, Tanimoto K, Hiyama K, Otani K, Ohtaki M, Hihara J, Yoshida K, Hiyama E, Noguchi T and Nishiyama M: Selection of a novel drug-response predictor in esophageal cancer: A novel screening method using microarray and identification of IFITM1 as a potent marker gene of CDDP response. Int J Oncol 32: 413-423, 2008.
4. Maughan TS, James RD, Kerr DJ, Ledermann JA, Seymour MT, Topham C, McArdle C, Cain D and Stephens RJ: British MRC Colorectal Cancer Working Party: Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomized trial. Lancet 359: 1555-1563, 2002.
5. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Custem E, Planker M, Santos JG, Piedbois P, Paillot B, Bodenstein H, Schmoll HJ, Bleiberg H, Nordlinger B, Couvreur ML, Baron B and Wils JA: Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 18: 2648-2657, 2000.
6. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 365: 1687-1717, 2005.
7. van Kuilenburg AB: Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40: 939-950, 2004.
8. Kubota T: 5-Fluorouracil and dihydropyrimidine dehydrogenase. Int J Clin Oncol 8: 127-131, 2003.
9. Ichikawa W, Takahashi T, Suto K, Nihei Z, Shirota Y, Shimizu M, Sasaki Y and Hirayama R: Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in relation to differentiation of gastric cancer. Int J Cancer 112: 967-973, 2004.
10. Ichikawa W, Takahashi T, Suto K, Yamashita T, Nihei Z, Shirota Y, Shimizu M, Sasaki Y and Hirayama R: Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. Br J Cancer 91: 1245-1250, 2004.
11. Ichikawa W, Uetake H, Shirota Y, Yamada H, Nishi N, Nihei Z, Sugihara K and Hirayama R: Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin Cancer Res 9: 786-791, 2003.
12. Kornmann M, Schwabe W, Sander S, Kron M, Strater J, Polat S, Kettner E, Weiser HF, Baumann W, Schramm H, Hausler P, Ott K, Behnke D, Staib L, Berger HG and Link KH: Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 9: 4116-4124, 2003.
13. Fujiwara H, Terashima M, Irinoda T, Takagane A, Abe K, Nakaya T, Yonezawa H, Oyama K, Takahashi M, Saito K, Takechi T, Fukushima M and Shirasaka T: Superior antitumour activity of S-1 in tumours with a high dihydropyrimidine dehydrogenase activity. Eur J Cancer 39: 2387-2394, 2003.
14. Nishina T, Hyodo I, Miyake J, Inaba T, Suzuki S and Shiratori Y: The ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase in tumour tissues of patients with metastatic gastric cancer is predictive of the clinical response to 5′-deoxy-5-fluorouridine. Eur J Cancer 40: 1566-1571, 2004.
15. Mizutani Y, Wada H, Fukushima M, Yoshida O, Nakanishi H, Li YN and Miki T: Prognostic significance of orotate phosphoribosyltransferase activity in bladder carcinoma. Cancer 100: 723-731, 2004.
16. Ichikawa W, Uetake H, Shirota Y, Yamada H, Takahashi T, Nihei Z, Sugihara K, Sasaki Y and Hirayama R: Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br J Cancer 89: 1486-1492, 2003.
17. Isshi K, Sakuyama T, Gen T, Nakamura Y, Kuroda T, Katuyama T and Maekawa Y: Predicting 5-FU sensitivity using human colorectal cancer specimens: comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphoribosyltransferase activities with in vitro chemosensitivity to 5-FU. Int J Clin Oncol 7: 335-342, 2002.
18. Spears CP, Shahinian AH, Moran RG, Heidelberger C and Corbett TH: In vivo kinetics of thymidylate synthase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. Cancer Res 42: 450-456, 1982.
19. Ciccolini J, Mercier C, Blachon MF, Favre R, Durand A and Lacarelle B: A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity. J Clin Pharm Ther 29: 307-315, 2004.
20. Taomoto J, Yoshida K, Wada Y, Tanabe K, Konishi K, Tahara H and Fukushima M: Overexpression of the orotate phosphoribosyltransferase gene enhance the effect of 5-fluorouracil on gastric cancer cell lines. Oncology 70: 458-464, 2006.
21. Inaba Makoto, Mitsuhashi J, Sawada H, Miike N, Naoe Y, Daimon A, Koizumi K, Tsujimoto H and Fukushima M: Reduced activity of anabolizing enzymes in 5-fluorouracil-resistant human stomach cancer cells. Jpn J Cancer Res 87: 212-220, 1996.
22. Chung YM, Park H, Park JK, Kim Y, Kang Y and Yoo YD: Establishment and characterization of 5-fluorouracil-resistant gastric cancer cells. Cancer Lett 159: 95-101, 2000.
23. Gottesman MM and Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 26: 385-427, 1993.
24. Urano N, Fujiwawa Y, Doki Y, Kim SJ, Miyoshi Y, Noguchi S, Miyata H, Takiguchi S, Yasuda T, Yano M and Monden M: Clinical significance of class III beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer. Int J Oncol 28: 375-381, 2006.
25. Mozzetti S, Ferlini C, Concolino P, Filippetti F, Raspaglio G, Prislei S, Gallo D, Martinelli E, Ranelletti FO, Ferrandina G and Scambia G: Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 11: 298-305, 2005.
26. Furukawa Y, Iwase S, Kikuchi J, Terui Y, Nakamura M, Yamada H, Kano Y and Matsuda M: Phosphorylation of Bcl-2 protein by CDC2 kinase during G2/ M phases and its role in cell cycle regulation. J Biol Chem 275: 21661-21667, 2000.
27. Yoshino T, Shiina H, Urakami S, Kikuno N, Yoneda T, Shigeno K and Igawa M: Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res 12: 6116-6124, 2006.